{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T09:05:33Z","timestamp":1789290333888,"version":"build-2803163510"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T00:00:00Z","timestamp":1528329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["surg case rep"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s40792-018-0460-1","type":"journal-article","created":{"date-parts":[[2018,6,7]],"date-time":"2018-06-07T08:16:56Z","timestamp":1528359416000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["S-1 induced discoid lupus erythematosus-like lesions and long-term complete response for para-aortic lymph node recurrence of pancreatic ductal adenocarcinoma: a case report"],"prefix":"10.1186","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3047-3434","authenticated-orcid":false,"given":"Ryosuke","family":"Yamaga","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Tezuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichiro","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiro","family":"Hirai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamio","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,7]]},"reference":[{"key":"460_CR1","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1097\/00001813-199607000-00010","volume":"7","author":"T Shirasaka","year":"1996","unstructured":"Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, et al. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs. 1996;7:548\u201357.","journal-title":"Anti-Cancer Drugs"},{"key":"460_CR2","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1097\/SLA.0000000000000263","volume":"259","author":"W Kimura","year":"2014","unstructured":"Kimura W, Miyata H, Gotoh M, Hirai I, Kenjo A, Kitagawa Y, et al. A pancreaticoduodenectomy risk model derived from 8575 cases from a national single-race population (Japanese) using a web-based data entry system: the 30-day and in-hospital mortality rates for pancreaticoduodenectomy. Ann Surg. 2014;259:773\u201380.","journal-title":"Ann Surg"},{"key":"460_CR3","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/S0140-6736(16)30583-9","volume":"388","author":"K Uesaka","year":"2016","unstructured":"Uesaka K, Boku N, Fukutomi A, Okamura Y, Konishi M, Matsumoto I, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388:248\u201357.","journal-title":"Lancet"},{"key":"460_CR4","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/jjco\/hyq005","volume":"40","author":"A Todaka","year":"2010","unstructured":"Todaka A, Fukutomi A, Boku N, Onozawa Y, Hironaka S, Yasui H, et al. S-1 monotherapy as second-line treatment for advanced pancreatic cancer after gemcitabine failure. Jpn J Clin Oncol. 2010;40:567\u201372.","journal-title":"Jpn J Clin Oncol"},{"key":"460_CR5","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00280-008-0741-7","volume":"63","author":"C Morizane","year":"2009","unstructured":"Morizane C, Okusaka T, Furuse J, Ishii H, Ueno H, Ikeda M, et al. A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol. 2009;63:313\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"key":"460_CR6","first-page":"54","volume":"11","author":"T Yoshimasu","year":"2001","unstructured":"Yoshimasu T, Hiroi A, Uede K, Furukawa F. Discoid lupus erythematosus (DLE)-like lesion induced by uracil-tegafur (UFT). Eur J Dermatol. 2001;11:54\u20137.","journal-title":"Eur J Dermatol"},{"key":"460_CR7","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00384-008-0462-8","volume":"23","author":"F Merlin","year":"2008","unstructured":"Merlin F, Prochilo T, Kildani B, Lombardi C, Pasolini G, Bonetti F, et al. Discoid lupus erythematosus (DLE)-like lesions induced by capecitabine. Int J Color Dis. 2008;23:715\u20136.","journal-title":"Int J Color Dis"},{"key":"460_CR8","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1159\/000096919","volume":"214","author":"A Adachi","year":"2007","unstructured":"Adachi A, Nagai H, Horikawa T. Anti-SSA\/Ro antibody as a risk factor for fluorouracil-induced drug eruptions showing acral erythema and discoid-lupus-erythematosus-like lesions. Dermatology. 2007;214:85\u20138.","journal-title":"Dermatology"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00403-008-0895-5","volume":"301","author":"CD Vedove","year":"2009","unstructured":"Vedove CD, Del Giglio M, Schena D, Girolomoni G. Drug-induced lupus erythematosus. Arch Dermatol Res. 2009;301:99\u2013105.","journal-title":"Arch Dermatol Res"},{"key":"460_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-40618-3","volume-title":"AJCC Cancer Staging Manual","author":"MB Amin","year":"2017","unstructured":"Amin MB, Edge SB, Green FL, Byrd DR, Brookland RK, Washington MK, et al. AJCC Cancer Staging Manual. 8th ed. New York: Springer; 2017.","edition":"8"},{"key":"460_CR11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"460_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.berh.2013.07.008","volume":"27","author":"LG Okon","year":"2013","unstructured":"Okon LG, Werth VP. Cutaneous lupus erythematosus: diagnosis and treatment. Best Pract Res Clin Rheumatol. 2013;27:391\u2013404.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"460_CR13","first-page":"115","volume":"14","author":"M Murata","year":"2015","unstructured":"Murata M, Nomiyama T, Takenaka H, Katoh N. A case of discoid lupus erythematosus-like drug eruptions due to TS-1. Skin Research (in Japanese with English abstract). 2015;14:115\u20138.","journal-title":"Skin Research (in Japanese with English abstract)"},{"key":"460_CR14","first-page":"1691","volume":"58","author":"H Arai","year":"2016","unstructured":"Arai H, Funasaka Y, Kanzaki A, Kanno H, Saeki H. A case of DLE-like eruption induced by tegafur\/gimeracil\/oteracil potassium (TS-1). Rinsho Derma. 2016;58:1691\u20135.","journal-title":"Rinsho Derma"},{"key":"460_CR15","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1200\/JCO.2012.43.3680","volume":"31","author":"H Ueno","year":"2013","unstructured":"Ueno H, Ioka T, Ikeda M, Ohkawa S, Yanagimoto H, Boku N, et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. J Clin Oncol. 2013;31:1640\u20138.","journal-title":"J Clin Oncol"},{"key":"460_CR16","first-page":"1620","volume":"42","author":"K Saso","year":"2015","unstructured":"Saso K, Murata M, Asai K, Yamada M, Yagi T, Katsuyama S, et al. A case of pancreatic cancer with multiple liver metastases that developed postoperatively and showed a complete response with S-1 monotherapy. Gan to Kagaku Ryoho. 2015;42:1620\u20132.","journal-title":"Gan to Kagaku Ryoho"},{"key":"460_CR17","first-page":"1582","volume":"42","author":"K Omori","year":"2015","unstructured":"Omori K, Wakabayashi K, Suematsu Y, Suda H, Hiratsuka M, Takebayashi M, et al. A case of gemcitabine refractory lung metastasis after distal pancreatectomy for pancreatic cancer, effectively treated with S-1 as second line chemotherapy. Gan to Kagaku Ryoho. 2015;42:1582\u20134.","journal-title":"Gan to Kagaku Ryoho"},{"key":"460_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.5833\/jjgs.2016.0122","volume":"50","author":"T Miyata","year":"2017","unstructured":"Miyata T, Okamura Y, Sugiura T, Ito T, Yamamoto Y, Ashida R, et al. Pathological complete response after S-1 therapy for an unresectable pancreatic head cancer with liver metastasis. Jpn J Gastroenterol Surg (in Japanese with English abstract). 2017;50:461\u20138.","journal-title":"Jpn J Gastroenterol Surg (in Japanese with English abstract)"},{"key":"460_CR19","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1097\/00006676-200308000-00012","volume":"27","author":"J Gardner-Thorpe","year":"2003","unstructured":"Gardner-Thorpe J, Ito H, Ashley SW, Whang EE. Autoantibody-mediated inhibition of pancreatic cancer cell growth in an athymic (nude) mouse model. Pancreas. 2003;27:180\u20139.","journal-title":"Pancreas"},{"key":"460_CR20","doi-asserted-by":"publisher","first-page":"5235","DOI":"10.1200\/JCO.2005.00.6916","volume":"23","author":"R Per\u00e9z-Soler","year":"2005","unstructured":"Per\u00e9z-Soler R, Saltz L. Cutaneous adverse effects with HER1\/EGFR-targeted agents: is there a silver lining? J Clin Oncol. 2005;23:5235\u201346.","journal-title":"J Clin Oncol"},{"key":"460_CR21","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007;25:1658\u201364.","journal-title":"J Clin Oncol"},{"key":"460_CR22","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1093\/annonc\/mdr366","volume":"23","author":"C Twelves","year":"2012","unstructured":"Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil\/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23:1190\u20137.","journal-title":"Ann Oncol"},{"key":"460_CR23","first-page":"1","volume":"2","author":"M Insawang","year":"2010","unstructured":"Insawang M, Kulthanan K, Chularojanamontri L, Tuchida P, Oinkaew S. Discoid lupus erythematosus: description of 130 cases and review of their natural history and clinical course. J Clin Immunol Immunopathol Res. 2010;2:1\u20139.","journal-title":"J Clin Immunol Immunopathol Res"},{"key":"460_CR24","first-page":"156","volume":"14","author":"WR Caruso","year":"1987","unstructured":"Caruso WR, Stewart ML, Nanda VK, Quismorio FP Jr. Squamous cell carcinoma of the skin in black patients with discoid lupus erythematosus. J Rheumatol. 1987;14:156\u20139.","journal-title":"J Rheumatol"}],"container-title":["Surgical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-018-0460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40792-018-0460-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40792-018-0460-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T19:04:42Z","timestamp":1559847882000},"score":1,"resource":{"primary":{"URL":"https:\/\/surgicalcasereports.springeropen.com\/articles\/10.1186\/s40792-018-0460-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,7]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s40792-018-0460-1","relation":{},"ISSN":["2198-7793"],"issn-type":[{"value":"2198-7793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,7]]},"assertion":[{"value":"19 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The case report was approved by the Hospital Ethics Committee of Yamagata University Faculty of Medicine.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Wataru Kimura received research funding from Taiho Pharmaceutical Co., Ltd, Chugai Pharmaceutical Co., Ltd, and Public Interest Foundation of Yamagata Health Promotion System.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"52"}}